Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
December 16, 2025

Pembrolizumab / keytruda for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies as of February 2022

MARA Rating Company December 16, 2025

Pembrolizumab / keytruda for treating triple-negative, locally recurrent unresectable or metastatic breast cancer as of June 2022

MARA Rating Company December 16, 2025

Pembrolizumab / keytruda for adjuvant treatment of renal cell carcinoma at increased risk of recurrence as of October 2022

MARA Rating Company December 16, 2025

Zeposia / ozanimod for treating relapsing-remitting multiple sclerosis as of June 2021

MARA Rating Company December 16, 2025

Zeposia / ozanimod for treating moderately to severely active ulcerative colitis as of October 2022

MARA Rating Company December 16, 2025

Palbociclib / ibrance for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy as of October 2022

MARA Rating Company December 16, 2025

Palforzia for treating peanut allergy in children and young people as of February 2022

MARA Rating Company December 16, 2025

Aspaveli / pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria as of March 2022

MARA Rating Company December 16, 2025

Pegunigalsidase alfa for treating Fabry disease as of October 2023

MARA Rating Company December 16, 2025

Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma as of May 2024

MARA Rating Company December 16, 2025